Susan Dana Jones is an experienced biotechnology entrepreneur who has co-founded two successful companies and has advised many others. She is a leading expert in cell line development and characterization, cell culture, and process development for biosimilar, new biopharmaceutical and vaccine development programs. She previously served as senior vice president of corporate development at Serenex Inc., where she helped complete a $15 million Series B financing. Prior to that, she was vice president of product development at Waratah Pharmaceuticals and held a variety of development and management positions at Peptimed, Virus Research Institute (now Celldex Immunotherapeutics), IntraImmune Therapies Inc. and Dyax. She serves on the board of directors of Gene Solutions LLC; the scientific advisory board of Symphogen A/S; and the editorial advisory board of BioProcess International. She holds a Ph.D. in genetics from the University of California, San Francisco.